Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Diclazuril Protects against Maternal Gastrointestinal Syndrome and Congenital Toxoplasmosis.
[congenital toxoplasmosis]
Toxoplasmosis
is
a
common
cause
of
foodborne
,
gastrointestinal
and
congenital
syndrome
with
particularly
severe
or
unknown
health
consequences
.
There
is
no
safe
and
effective
preventive
or
therapeutic
modality
against
congenital
toxoplasmosis
or
to
eliminate
the
persistent
chronic
infection
.
Diclazuril
to
be
safe
in
pregnancy
and
effective
against
gastrointestinal
toxoplasmosis
.
CD
1
programmed
pregnant
mice
were
divided
into
groups
and
administered
a
diet
containing
diclazuril
,
or
sham
control
.
Treatments
were
initiated
on
Day
5
of
pregnancy
and
continued
until
Day
16
when
dams
were
euthanatized
.
On
Day
8
of
pregnancy
dams
were
infected
intraperitoneally
with
escalating
doses
of
tachyzoites
(
0
,
100
,
300
,
600
)
from
Type
II
strain
.
Dams
were
monitored
daily
for
distress
,
pain
,
and
abortion
and
samples
collected
at
the
end
of
the
experiments
.
Infected
dams
developed
moderate
to
severe
Toxoplasma
related
complications
in
tachyzoites
dose
dependent
manner
.
Animals
became
anemic
and
showed
hydrothorax
,
and
ascities
.
Diclazuril
effectively
protected
dams
from
ascities
and
anemia
(
p
<
0
.
05
)
.
Infected
dams
showed
splenomegaly
,
with
massive
infiltration
of
epithelioid
cells
compared
with
the
protective
effect
of
diclazuril
in
treated
animals
.
Infected
dams
exhibited
severe
hepatitis
(
score
0
to
4
scale
=
3
.
5
±
0
.
01
)
with
influx
of
inflammatory
and
plasma
cells
,
dysplastic
hepatocytes
,
multinucleated
giant
cell
transformation
and
hepatic
cells
necrosis
.
Diclazuril
treatment
significantly
protected
dams
from
hepatitis
,
also
in
tachyzoites
dose
(
100
,
300
,
600
)
dependent
manner
(
respectively
infected-treated
versus
infected
controls
,
p
<
0
.
001
,
p
<
0
.
01
and
p
<
0
.
05
)
.
Colonic
tissues
were
significantly
shortened
in
length
,
with
infiltration
of
lymphocytes
,
and
macrophages
and
microabscess
formations
in
the
cryptic
structures
,
with
significant
improvement
in
diclazuril
treated
animals
.
Additionally
,
the
number
of
fetuses
,
fetal
length
and
fetal
weight
were
preserved
in
diclazuril
treated
dams
.
This
is
the
first
report
describing
of
diclazuril
safety
in
pregnancy
as
well
as
efficacy
against
mild
to
moderate
hepato-
gastrointestinal
syndrome
in
dams
and
fetal
toxoplasmosis
(
Special
issue
,
"
Treatment
of
Liver
Diseases
"
)
.
Diseases
Validation
Diseases presenting
"pain"
symptom
achondroplasia
acute rheumatic fever
adrenal incidentaloma
adrenomyeloneuropathy
aniridia
aromatase deficiency
carcinoma of the gallbladder
cholangiocarcinoma
coats disease
congenital diaphragmatic hernia
congenital toxoplasmosis
cushing syndrome
cutaneous mastocytosis
cystinuria
dedifferentiated liposarcoma
dentin dysplasia
dracunculiasis
dystrophic epidermolysis bullosa
epidermolysis bullosa simplex
erdheim-chester disease
erythropoietic protoporphyria
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
fabry disease
familial mediterranean fever
focal myositis
hirschsprung disease
hodgkin lymphoma, classical
holt-oram syndrome
junctional epidermolysis bullosa
kabuki syndrome
kindler syndrome
lamellar ichthyosis
liposarcoma
locked-in syndrome
lymphangioleiomyomatosis
malignant atrophic papulosis
neuralgic amyotrophy
oligodontia
oral submucous fibrosis
papillon-lefèvre syndrome
phenylketonuria
pleomorphic liposarcoma
primary hyperoxaluria type 1
proteus syndrome
pyomyositis
scrub typhus
sneddon syndrome
systemic capillary leak syndrome
thoracic outlet syndrome
trochlear dysplasia
typhoid
von hippel-lindau disease
waldenström macroglobulinemia
well-differentiated liposarcoma
wolf-hirschhorn syndrome
This symptom has already been validated